HEALTHSTAT NEWS
Opinion: The U.S. pharmaceutical supply chain problem is not about China
The U.S. faced 216 active drug shortages in 2025, highlighting vulnerabilities in its pharmaceutical supply chain. The article argues that framing the issue as a U.S.-China competition distracts from the real cause: inadequate regulation leading to profit prioritization over public health.
Mentioned
Related Signal
Adjacent reporting
- Why the West has an uphill task challenging China in pharmaceutical ingredients
- STAT+: The shortage of many medicines in the U.S. remains a ‘systemic’ problem, a new analysis finds
- Opinion: STAT+: Pharma and biotech leaders are destroying their own industry
- STAT+: Pharmalittle: We’re reading about rising drug shortages, GSK coughing up a trial loss, and more
- STAT+: Pharmalittle: We’re reading about U.S. biotech’s China problem, a Regeneron flop, and much more